Abstract
Cancer immunotherapy can successfully promote long-term anticancer immune responses, although there is still only a limited number of patients who benefit from such treatment, and it can sometimes have severe treatment-associated adverse events. Compared with systemic immunomodulation, local immunomodulation may enable more effective treatment at lower doses and, at the same time, prevent systemic toxicity. Local delivery of engineered three-dimensional scaffolds may fulfil this role by acting as synthetic immune niches that boost anticancer immunity. In this Opinion article, we highlight the potential of scaffold-based adoptive cell transfer and scaffold-based cancer vaccines that, although applied locally, can promote systemic antitumour immunity. Furthermore, we discuss how scaffold-based cancer immunotherapy may contribute to the development of the next generation of cancer treatments.
Original language | English |
---|---|
Pages (from-to) | 212-219 |
Number of pages | 8 |
Journal | Nature Reviews. Immunology |
Volume | 18 |
Issue number | 3 |
Early online date | 30 Aug 2017 |
DOIs | |
Publication status | Published - 1 Mar 2018 |
Keywords
- Journal Article
- Review